Search for Clinical Trial Results
Mantle Cell Lymphoma - 35 Studies Found
Status | Study |
NOT_YET_RECRUITING |
Study Name: Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2024-06-16 Interventions: Given PO |
NOT_YET_RECRUITING |
Study Name: Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Condition: Recurrent Mantle Cell Lymphoma Date: 2024-06-16 Interventions: Undergo biopsy |
RECRUITING |
Study Name: Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients Condition: Mantle Cell Lymphoma Date: 2024-06-16 Interventions: Given by PO |
COMPLETED |
Study Name: The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2024-06-16 Interventions: The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for do |
COMPLETED |
Study Name: Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2024-06-16 Interventions: Acalabrutinib 100 mg BID will be self-administered orally starting from 100 day (+/- 7 days) Post-BMT on a 28-day schedule, with or without food, |